
Mativ Boston Consulting Group Matrix
Curious where Mativ’s products actually sit—Stars, Cash Cows, Dogs, or Question Marks? This preview teases the shape of the portfolio; buy the full BCG Matrix to get quadrant-by-quadrant placement, data-driven recommendations, and a clear playbook for where to invest, divest, or defend. Get instant access to a ready-to-use Word report and Excel summary that saves you hours and gives the confidence to act fast.
Stars
High-growth demand from EVs, hyperscale data centers, and tighter air regulations has put advanced filtration media in the slipstream; global BEV sales passed 14 million in 2023 and filtration demand rose further into 2024. Mativ’s engineered media and application depth give it a leadership edge in specs and qualification. It needs sustained capex, pilot lines, and marketing to defend and grow share — feed it to graduate into outsized cash.
Healthcare customers are sticky and regulatory barriers are high, with the global wound-care market growing at roughly a 5% CAGR and on track for >$20B by 2028; Mativ’s specialty substrates and coatings fit high-value, certified applications (IVD, dressings, surgical) and command premium pricing. These programs absorb working capital and multi-million-dollar validation cycles (12–24 months), so continue investing in capacity, quality systems, and co-development with top OEMs.
Precision liners for tapes, wearables and medical devices align with multi-year secular growth (wearable sensors market CAGR ~8% to 2028), and Mativ’s coating know-how and reliability make it a go-to spec partner; volumes ramp fast when customers scale, often multiplying by 3x–5x in launch years. Application labs and rapid sampling shorten qualification cycles, locking in first-to-line positions and recurring revenue.
Sustainable premium packaging substrates
Brands demand plastic reduction and curbside recyclability, yesterday; fiber-based, high-appearance substrates with functional barrier options are meeting that need in 2024 and winning shelf share as market growth accelerates. Early movers capture premium listings and pricing; prioritize barrier innovation, enhanced print performance, and regional converting partnerships to scale fast.
- Market trend: 2024 demand spike for recyclable fiber substrates
- Focus: barrier R&D, print quality, regional converting
- Strategy: early investment = shelf share and pricing power
Filtration and protection for electronics and cleanrooms
Semiconductor and advanced manufacturing have tightened particulate and EHS specs, boosting demand for high-performance filtration media and specialty nonwovens. These products can command 15–35% price premiums; qualification cycles typically run 12–24 months and create sticky revenue. Continue building credibility through trials, audits, and global supply assurance as 2024 fab capex expansions sustain demand.
EVs, hyperscale data centers, healthcare and sustainability drove 2024 demand for Mativ stars; BEV sales hit 14M in 2023 and filtration demand rose further into 2024. These businesses earn 15–35% premiums, have 12–24 month qualifications, and require sustained capex and pilot lines to scale. Sticky healthcare and tape programs yield recurring revenue but tie up working capital. Early shelf-share wins and regional converting speed commercialization.
| Segment | Key 2024 metric | Outlook | Action |
|---|---|---|---|
| Filtration | 15–35% premium | fab capex up | capex, audits |
| Healthcare | Wound-care >$20B by 2028 | 5% CAGR | validation, quality |
What is included in the product
Concise BCG-style review of Mativ's units—Stars, Cash Cows, Question Marks, Dogs—with investment recommendations and trend context.
One-page Mativ BCG Matrix pinpoints growth and cash cows fast, easing portfolio decisions for founders and CFOs.
Cash Cows
Industrial release liners for tapes and labels are classic cash cows: mature, high-share franchises that generate steady free cash in a global release-liner market valued around US$3.8 billion in 2024 with low-single-digit CAGR. Operational excellence and tight yield management, not bold R&D, drive profit; sustaining engineering and light product refreshes preserve 15–25% margins. Milk with discipline, automate where possible, and fiercely defend core accounts.
HVAC and industrial replacement filtration delivers steady recurring revenue from replacement cycles typically every 3–12 months and broad distribution networks, making it a dependable earner; the global air filtration market was estimated near $11 billion in 2024 with mid-single-digit growth. Volumes are predictable, so price management and SKU rationalization are primary profit levers. Maintain service levels, optimize product mix, and reinvest only for automation and efficiency gains to protect margins.
Specialty papers for labels and graphics occupy stable niches with entrenched specifications and long-standing customers, delivering cash reliability; in 2024 this segment contributed a substantial portion of Mativ’s cash flow (net sales approx. $2.1B companywide in 2024). Product differentiation is defensible but limits growth, so priorities must be cost, consistent quality, and tight lead times. Harvest excess cash and reallocate to higher-growth platforms and R&D to drive future expansion.
Tobacco-related engineered papers
Tobacco-related engineered papers remain cash cows for Mativ: large global share positions generate steady free cash flow despite mid-to-low single-digit volume declines in 2023–24, as processes are highly optimized and largely depreciated. Long-term pricing and multi-year contracts cushion volume drift, enabling reduced maintenance capex and strong margin protection. Surplus cash is prioritized for next-gen materials and targeted R&D to offset portfolio secular decline.
- Low-to-negative growth: mid-single-digit volume decline (2023–24)
- High cash conversion: optimized, well-depreciated assets
- Pricing/contracts: revenue stability vs volume risk
- Capex: managed down to preserve margins
- Capital allocation: surplus to next-gen materials/R&D
Protective films and functional coatings for industry
Protective films and functional coatings are cash cows for Mativ: a large installed base keeps orders steady in a mature market (industry growth ~3% CAGR in 2024), differentiation rests on process know-how and consistency, and incremental innovation preserves price premiums and loyalty; focus is on harvesting cash with tight operations and selective customer upgrades.
- installed base: recurring demand
- 2024 industry growth ~3% CAGR
- value from process consistency
- incremental innovation = premium retention
- strategy: run for cash, tight ops, select upgrades
Mativ cash cows (2024): mature franchises (release liners $3.8B market, HVAC filtration ~$11B, specialty papers supporting company net sales ~$2.1B) generate steady free cash with 15–25% operating margins, low-to-mid single-digit market growth, and high cash conversion; prioritize disciplined harvest, automation, SKU rationalization, and targeted reinvestment into next-gen R&D.
| Segment | 2024 market | Growth | Op margin |
|---|---|---|---|
| Release liners | $3.8B | low-SD | 15–25% |
| HVAC filtration | $11B | mid-SD | 15–25% |
What You See Is What You Get
Mativ BCG Matrix
The file you’re previewing is the exact Mativ BCG Matrix document you’ll receive after purchase. No watermarks, no demo copy—just a fully formatted, analysis-ready report built for clarity. After buying, the same file is available for immediate download and editing. It’s designed by strategy pros to plug straight into your planning, presentations, or client work without surprises.
Curious where Mativ’s products actually sit—Stars, Cash Cows, Dogs, or Question Marks? This preview teases the shape of the portfolio; buy the full BCG Matrix to get quadrant-by-quadrant placement, data-driven recommendations, and a clear playbook for where to invest, divest, or defend. Get instant access to a ready-to-use Word report and Excel summary that saves you hours and gives the confidence to act fast.
Stars
High-growth demand from EVs, hyperscale data centers, and tighter air regulations has put advanced filtration media in the slipstream; global BEV sales passed 14 million in 2023 and filtration demand rose further into 2024. Mativ’s engineered media and application depth give it a leadership edge in specs and qualification. It needs sustained capex, pilot lines, and marketing to defend and grow share — feed it to graduate into outsized cash.
Healthcare customers are sticky and regulatory barriers are high, with the global wound-care market growing at roughly a 5% CAGR and on track for >$20B by 2028; Mativ’s specialty substrates and coatings fit high-value, certified applications (IVD, dressings, surgical) and command premium pricing. These programs absorb working capital and multi-million-dollar validation cycles (12–24 months), so continue investing in capacity, quality systems, and co-development with top OEMs.
Precision liners for tapes, wearables and medical devices align with multi-year secular growth (wearable sensors market CAGR ~8% to 2028), and Mativ’s coating know-how and reliability make it a go-to spec partner; volumes ramp fast when customers scale, often multiplying by 3x–5x in launch years. Application labs and rapid sampling shorten qualification cycles, locking in first-to-line positions and recurring revenue.
Sustainable premium packaging substrates
Brands demand plastic reduction and curbside recyclability, yesterday; fiber-based, high-appearance substrates with functional barrier options are meeting that need in 2024 and winning shelf share as market growth accelerates. Early movers capture premium listings and pricing; prioritize barrier innovation, enhanced print performance, and regional converting partnerships to scale fast.
- Market trend: 2024 demand spike for recyclable fiber substrates
- Focus: barrier R&D, print quality, regional converting
- Strategy: early investment = shelf share and pricing power
Filtration and protection for electronics and cleanrooms
Semiconductor and advanced manufacturing have tightened particulate and EHS specs, boosting demand for high-performance filtration media and specialty nonwovens. These products can command 15–35% price premiums; qualification cycles typically run 12–24 months and create sticky revenue. Continue building credibility through trials, audits, and global supply assurance as 2024 fab capex expansions sustain demand.
EVs, hyperscale data centers, healthcare and sustainability drove 2024 demand for Mativ stars; BEV sales hit 14M in 2023 and filtration demand rose further into 2024. These businesses earn 15–35% premiums, have 12–24 month qualifications, and require sustained capex and pilot lines to scale. Sticky healthcare and tape programs yield recurring revenue but tie up working capital. Early shelf-share wins and regional converting speed commercialization.
| Segment | Key 2024 metric | Outlook | Action |
|---|---|---|---|
| Filtration | 15–35% premium | fab capex up | capex, audits |
| Healthcare | Wound-care >$20B by 2028 | 5% CAGR | validation, quality |
What is included in the product
Concise BCG-style review of Mativ's units—Stars, Cash Cows, Question Marks, Dogs—with investment recommendations and trend context.
One-page Mativ BCG Matrix pinpoints growth and cash cows fast, easing portfolio decisions for founders and CFOs.
Cash Cows
Industrial release liners for tapes and labels are classic cash cows: mature, high-share franchises that generate steady free cash in a global release-liner market valued around US$3.8 billion in 2024 with low-single-digit CAGR. Operational excellence and tight yield management, not bold R&D, drive profit; sustaining engineering and light product refreshes preserve 15–25% margins. Milk with discipline, automate where possible, and fiercely defend core accounts.
HVAC and industrial replacement filtration delivers steady recurring revenue from replacement cycles typically every 3–12 months and broad distribution networks, making it a dependable earner; the global air filtration market was estimated near $11 billion in 2024 with mid-single-digit growth. Volumes are predictable, so price management and SKU rationalization are primary profit levers. Maintain service levels, optimize product mix, and reinvest only for automation and efficiency gains to protect margins.
Specialty papers for labels and graphics occupy stable niches with entrenched specifications and long-standing customers, delivering cash reliability; in 2024 this segment contributed a substantial portion of Mativ’s cash flow (net sales approx. $2.1B companywide in 2024). Product differentiation is defensible but limits growth, so priorities must be cost, consistent quality, and tight lead times. Harvest excess cash and reallocate to higher-growth platforms and R&D to drive future expansion.
Tobacco-related engineered papers
Tobacco-related engineered papers remain cash cows for Mativ: large global share positions generate steady free cash flow despite mid-to-low single-digit volume declines in 2023–24, as processes are highly optimized and largely depreciated. Long-term pricing and multi-year contracts cushion volume drift, enabling reduced maintenance capex and strong margin protection. Surplus cash is prioritized for next-gen materials and targeted R&D to offset portfolio secular decline.
- Low-to-negative growth: mid-single-digit volume decline (2023–24)
- High cash conversion: optimized, well-depreciated assets
- Pricing/contracts: revenue stability vs volume risk
- Capex: managed down to preserve margins
- Capital allocation: surplus to next-gen materials/R&D
Protective films and functional coatings for industry
Protective films and functional coatings are cash cows for Mativ: a large installed base keeps orders steady in a mature market (industry growth ~3% CAGR in 2024), differentiation rests on process know-how and consistency, and incremental innovation preserves price premiums and loyalty; focus is on harvesting cash with tight operations and selective customer upgrades.
- installed base: recurring demand
- 2024 industry growth ~3% CAGR
- value from process consistency
- incremental innovation = premium retention
- strategy: run for cash, tight ops, select upgrades
Mativ cash cows (2024): mature franchises (release liners $3.8B market, HVAC filtration ~$11B, specialty papers supporting company net sales ~$2.1B) generate steady free cash with 15–25% operating margins, low-to-mid single-digit market growth, and high cash conversion; prioritize disciplined harvest, automation, SKU rationalization, and targeted reinvestment into next-gen R&D.
| Segment | 2024 market | Growth | Op margin |
|---|---|---|---|
| Release liners | $3.8B | low-SD | 15–25% |
| HVAC filtration | $11B | mid-SD | 15–25% |
What You See Is What You Get
Mativ BCG Matrix
The file you’re previewing is the exact Mativ BCG Matrix document you’ll receive after purchase. No watermarks, no demo copy—just a fully formatted, analysis-ready report built for clarity. After buying, the same file is available for immediate download and editing. It’s designed by strategy pros to plug straight into your planning, presentations, or client work without surprises.
Description
Curious where Mativ’s products actually sit—Stars, Cash Cows, Dogs, or Question Marks? This preview teases the shape of the portfolio; buy the full BCG Matrix to get quadrant-by-quadrant placement, data-driven recommendations, and a clear playbook for where to invest, divest, or defend. Get instant access to a ready-to-use Word report and Excel summary that saves you hours and gives the confidence to act fast.
Stars
High-growth demand from EVs, hyperscale data centers, and tighter air regulations has put advanced filtration media in the slipstream; global BEV sales passed 14 million in 2023 and filtration demand rose further into 2024. Mativ’s engineered media and application depth give it a leadership edge in specs and qualification. It needs sustained capex, pilot lines, and marketing to defend and grow share — feed it to graduate into outsized cash.
Healthcare customers are sticky and regulatory barriers are high, with the global wound-care market growing at roughly a 5% CAGR and on track for >$20B by 2028; Mativ’s specialty substrates and coatings fit high-value, certified applications (IVD, dressings, surgical) and command premium pricing. These programs absorb working capital and multi-million-dollar validation cycles (12–24 months), so continue investing in capacity, quality systems, and co-development with top OEMs.
Precision liners for tapes, wearables and medical devices align with multi-year secular growth (wearable sensors market CAGR ~8% to 2028), and Mativ’s coating know-how and reliability make it a go-to spec partner; volumes ramp fast when customers scale, often multiplying by 3x–5x in launch years. Application labs and rapid sampling shorten qualification cycles, locking in first-to-line positions and recurring revenue.
Sustainable premium packaging substrates
Brands demand plastic reduction and curbside recyclability, yesterday; fiber-based, high-appearance substrates with functional barrier options are meeting that need in 2024 and winning shelf share as market growth accelerates. Early movers capture premium listings and pricing; prioritize barrier innovation, enhanced print performance, and regional converting partnerships to scale fast.
- Market trend: 2024 demand spike for recyclable fiber substrates
- Focus: barrier R&D, print quality, regional converting
- Strategy: early investment = shelf share and pricing power
Filtration and protection for electronics and cleanrooms
Semiconductor and advanced manufacturing have tightened particulate and EHS specs, boosting demand for high-performance filtration media and specialty nonwovens. These products can command 15–35% price premiums; qualification cycles typically run 12–24 months and create sticky revenue. Continue building credibility through trials, audits, and global supply assurance as 2024 fab capex expansions sustain demand.
EVs, hyperscale data centers, healthcare and sustainability drove 2024 demand for Mativ stars; BEV sales hit 14M in 2023 and filtration demand rose further into 2024. These businesses earn 15–35% premiums, have 12–24 month qualifications, and require sustained capex and pilot lines to scale. Sticky healthcare and tape programs yield recurring revenue but tie up working capital. Early shelf-share wins and regional converting speed commercialization.
| Segment | Key 2024 metric | Outlook | Action |
|---|---|---|---|
| Filtration | 15–35% premium | fab capex up | capex, audits |
| Healthcare | Wound-care >$20B by 2028 | 5% CAGR | validation, quality |
What is included in the product
Concise BCG-style review of Mativ's units—Stars, Cash Cows, Question Marks, Dogs—with investment recommendations and trend context.
One-page Mativ BCG Matrix pinpoints growth and cash cows fast, easing portfolio decisions for founders and CFOs.
Cash Cows
Industrial release liners for tapes and labels are classic cash cows: mature, high-share franchises that generate steady free cash in a global release-liner market valued around US$3.8 billion in 2024 with low-single-digit CAGR. Operational excellence and tight yield management, not bold R&D, drive profit; sustaining engineering and light product refreshes preserve 15–25% margins. Milk with discipline, automate where possible, and fiercely defend core accounts.
HVAC and industrial replacement filtration delivers steady recurring revenue from replacement cycles typically every 3–12 months and broad distribution networks, making it a dependable earner; the global air filtration market was estimated near $11 billion in 2024 with mid-single-digit growth. Volumes are predictable, so price management and SKU rationalization are primary profit levers. Maintain service levels, optimize product mix, and reinvest only for automation and efficiency gains to protect margins.
Specialty papers for labels and graphics occupy stable niches with entrenched specifications and long-standing customers, delivering cash reliability; in 2024 this segment contributed a substantial portion of Mativ’s cash flow (net sales approx. $2.1B companywide in 2024). Product differentiation is defensible but limits growth, so priorities must be cost, consistent quality, and tight lead times. Harvest excess cash and reallocate to higher-growth platforms and R&D to drive future expansion.
Tobacco-related engineered papers
Tobacco-related engineered papers remain cash cows for Mativ: large global share positions generate steady free cash flow despite mid-to-low single-digit volume declines in 2023–24, as processes are highly optimized and largely depreciated. Long-term pricing and multi-year contracts cushion volume drift, enabling reduced maintenance capex and strong margin protection. Surplus cash is prioritized for next-gen materials and targeted R&D to offset portfolio secular decline.
- Low-to-negative growth: mid-single-digit volume decline (2023–24)
- High cash conversion: optimized, well-depreciated assets
- Pricing/contracts: revenue stability vs volume risk
- Capex: managed down to preserve margins
- Capital allocation: surplus to next-gen materials/R&D
Protective films and functional coatings for industry
Protective films and functional coatings are cash cows for Mativ: a large installed base keeps orders steady in a mature market (industry growth ~3% CAGR in 2024), differentiation rests on process know-how and consistency, and incremental innovation preserves price premiums and loyalty; focus is on harvesting cash with tight operations and selective customer upgrades.
- installed base: recurring demand
- 2024 industry growth ~3% CAGR
- value from process consistency
- incremental innovation = premium retention
- strategy: run for cash, tight ops, select upgrades
Mativ cash cows (2024): mature franchises (release liners $3.8B market, HVAC filtration ~$11B, specialty papers supporting company net sales ~$2.1B) generate steady free cash with 15–25% operating margins, low-to-mid single-digit market growth, and high cash conversion; prioritize disciplined harvest, automation, SKU rationalization, and targeted reinvestment into next-gen R&D.
| Segment | 2024 market | Growth | Op margin |
|---|---|---|---|
| Release liners | $3.8B | low-SD | 15–25% |
| HVAC filtration | $11B | mid-SD | 15–25% |
What You See Is What You Get
Mativ BCG Matrix
The file you’re previewing is the exact Mativ BCG Matrix document you’ll receive after purchase. No watermarks, no demo copy—just a fully formatted, analysis-ready report built for clarity. After buying, the same file is available for immediate download and editing. It’s designed by strategy pros to plug straight into your planning, presentations, or client work without surprises.











